Here we addressed the issue of the relationship between the kinetics of serum CD69+ EVs and ATLG pharmacokinetics in the pre-transplant phase in order to investigate if CD69+ EVs represent a marker of GVHD as well as ATLG pharmacokinetics. This evidence concerns the gene CD69 and graft versus host disease.